Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function.
Myotonic dystrophy type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely ...
Posters presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference highlight the complex care needs and physical activity barriers for individuals with myotonic dystrophy.
Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely affects multiple organs including skeletal muscle, heart, brain and the ...
News Medical on MSN5d
Testing a novel approach to restore normal heart function in Myotonic Dystrophy Type 1Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely affects multiple organs including skeletal muscle, heart, brain and the ...
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $18.00 to $17.00 ...
Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it ...
Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, ...
Learn more about whether Elanco Animal Health Incorporated or Harmony Biosciences Holdings, Inc. is a better investment based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback